Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBACAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 197,900 shares of Akebia’s common stock on December 31, 2025. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AKBA(NASDAQ:AKBA) CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 95,100 shares of Akebia’s common stock on August 29, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
AKBACAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and Innovative Renal Care (IRC), a leading comprehensive kidney care provider in the U.S., today announced the broad availability of Vafseo® (vadadustat) for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients across all IRC clinics.
Akebia Therapeutics Announces Publication In JASN Of U.S. And Non-U.S. Subgroup Analyses From Vadadustat Global Phase 3 Trials, Showing Comparable Safety And Efficacy In Dialysis-Dependent CKD Patients And Highlighting Elevated MACE Risk In U.S. Non–Dialy
AKBAVadadustat Releases U.S. Patient Data From Global Phase 3 Clinical Program In Journal of the American Society Of Nephrology
AKBAHC Wainwright & Co. Assumes Akebia Therapeutics at Buy, Announces Price Target of $8
AKBA12 Health Care Stocks Moving In Thursday's Pre-Market Session
AKBAAkebia Therapeutics Q1 EPS $0.03 Beats $(0.04) Estimate, Sales $57.34M Beat $44.88M Estimate
AKBAInsights Ahead: Akebia Therapeutics's Quarterly Earnings
AKBAHC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target
AKBAAkebia Therapeutics Announces Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted A Positive Opinion Recommending The European Commission To Approve Xoanacyl For Treatment Of Concomitant Elevated Serum Phosphorous A
AKBAJefferies Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $6
AKBACrude Oil Gains Over 1%; US Weekly Jobless Claims Increase
AKBAJOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
AKBAReported Earlier, Akebia Therapeutics Prices $50M Public Offering Of 25M Common Shares At $2/Share
AKBA12 Health Care Stocks Moving In Wednesday's After-Market Session
AKBAAkebia Therapeutics Commences Public Offering; No Terms Disclosed
AKBAHallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
AKBAPiper Sandler Maintains Overweight on Akebia Therapeutics, Raises Price Target to $6
AKBAHC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target
AKBAAkebia's Cash And Cash Equivalents As Of December 31, 2024, Were Approximately $51.9M That Will Be Sufficient To Fund Current Operating Plan For At Least Two Years
AKBAAkebia Therapeutics Q4 2024 GAAP EPS $(0.10) Misses $(0.08) Estimate, Sales $46.50M Beat $37.35M Estimate
AKBAHC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target
AKBAAkebia Announced Near 100% U.S. Dialysis Coverage For Vafseo, Vafseo Shipments Commence, Phase 3 Trial For Late-Stage Non-Dialysis CKD Patients Planned for Mid-2025
AKBAAkebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In Hemodial
AKBA